Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AG0F | ISIN: SE0006091997 | Ticker-Symbol: 1YR
Frankfurt
20.11.24
08:24 Uhr
0,030 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
5-Tage-Chart
IMMUNOVIA AB 5-Tage-Chart

Aktuelle News zur IMMUNOVIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrIMMUNOVIA AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers3
12.11.Immunovia AB: Invitation to Immunovia's Q3 presentation105LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast...
► Artikel lesen
IMMUNOVIA Aktie jetzt für 0€ handeln
07.11.Immunovia AB: Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium209SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual...
► Artikel lesen
07.10.Immunovia AB: Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer306LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples...
► Artikel lesen
02.10.Immunovia AB: Immunovia completes analytical validation of its next-generation pancreatic cancer test248LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation...
► Artikel lesen
30.09.Change in number of shares and votes in Immunovia AB (publ)200LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of...
► Artikel lesen
27.09.Nasdaq Stockholm AB: New equity right for trading, Immunovia AB (publ)229At the request of Immunovia AB (publ), Immunovia AB equity rights TO 2 and TO 3 will be traded on Nasdaq Stockholm as from September 30, 2024. IMMNOV TO 2 Security name: Immunovia AB TO 2 --------------------------------- Short...
► Artikel lesen
16.09.Immunovia AB: Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference343LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the...
► Artikel lesen
12.09.IMMUNOVIA AB: Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue2
03.09.IMMUNOVIA AB: Immunovia announces final outcome in rights issue2
02.09.IMMUNOVIA AB: Immunovia publishes preliminary outcome in rights issue1
13.08.Nasdaq Stockholm AB: Listing of units rights and paid subscription units of Immunovia AB349With effect from August 16, 2024, the unit rights of Immunovia AB will be traded on the list for Equity rights. Trading will continue up until and including August 27, 2024. Instrument: Unit rights...
► Artikel lesen
12.08.IMMUNOVIA AB: Immunovia publishes prospectus in connection with forthcoming rights issue1
12.08.XFRA CAPITAL ADJUSTMENT INFORMATION - 12.08.2024409Das Instrument 1YR SE0006091997 IMMUNOVIA AB EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024 The instrument 1YR SE0006091997 IMMUNOVIA AB EQUITY is traded...
► Artikel lesen
06.08.IMMUNOVIA AB: Immunovia announces final terms of rights issue4
05.08.Immunovia AB: Immunovia Publishes Interim Report for January-June 2024880LUND, Sweden, Aug. 5, 2024 /PRNewswire/ -- April-June 2024 Net sales, consisting of royalties, amounted to 85 KSEK (412)Net earnings amounted to -25.6 MSEK (-185.1), where one-off...
► Artikel lesen
05.08.Immunovia AB: Immunovia's next-generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health108LUND, Sweden, Aug. 5, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces that the company's next-generation test to detect pancreatic...
► Artikel lesen
02.08.Immunovia AB: Immunovia files US patent application to protect its next-generation test195LUND, Sweden, Aug. 2, 2024 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today announces the company has filed a US provisional patent application...
► Artikel lesen
01.08.Immunovia AB: Immunovia completes development of its pancreatic cancer detection test after substantially increasing test accuracy414LUND, Sweden, Aug. 1, 2024 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today announces enhanced performance for its next-generation test...
► Artikel lesen
29.07.Immunovia AB: Invitation to Immunovia's Q2 presentation221LUND, Sweden, July 29, 2024 /PRNewswire/ -- Immunovia will publish its second quarter 2024 results on August 5, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1